Abstract：
OBJECTIVE: This study aimed to propose a novel approach of lipiodol combined with drug-eluting beads transarterial chemoembolization (Lipiodol-DEB TACE) and to compare the safety and efficacy with DEB-TACE alone for patients with unresectable hepatocellular carcinoma (HCC).
METHODS: From the database of four centers, the records of patients with HCC who received DEB-TACE or Lipiodol-DEB TACE as initial treatment were retrospectively evaluated. The tumor response was measured based on the Modified Response Evaluation Criteria in Solid Tumors. Overall survival (OS), progression-free survival (PFS) and adverse events (AEs) were compared between two groups.
RESULTS: A total of 244 patients were included with 160 patients receiving DEB-TACE and 84 patients receiving Lipiodol-DEB TACE. Lipiodol-DEB TACE group had higher objective response rate (86.9 % vs. 76.3 %), higher disease control rate (97.6 % vs. 88.8 %), longer median OS (42.6 vs. 25.8 months) and longer median PFS (34.0 vs. 17.0 months) than DEB-TACE group (P < 0.05). There was no significant difference observed in the incidence of AEs between two groups. Cox analysis identified total bilirubin level, maximum tumor diameter, TACE method and portal vein invasion as independent prognostic factors.
CONCLUSIONS: Lipiodol-DEB TACE was a safe option and associated with improved tumor response and survival outcome compared to DEB-TACE alone for selected patients with HCC.
METHODS: From the database of four centers, the records of patients with HCC who received DEB-TACE or Lipiodol-DEB TACE as initial treatment were retrospectively evaluated. The tumor response was measured based on the Modified Response Evaluation Criteria in Solid Tumors. Overall survival (OS), progression-free survival (PFS) and adverse events (AEs) were compared between two groups.
RESULTS: A total of 244 patients were included with 160 patients receiving DEB-TACE and 84 patients receiving Lipiodol-DEB TACE. Lipiodol-DEB TACE group had higher objective response rate (86.9 % vs. 76.3 %), higher disease control rate (97.6 % vs. 88.8 %), longer median OS (42.6 vs. 25.8 months) and longer median PFS (34.0 vs. 17.0 months) than DEB-TACE group (P < 0.05). There was no significant difference observed in the incidence of AEs between two groups. Cox analysis identified total bilirubin level, maximum tumor diameter, TACE method and portal vein invasion as independent prognostic factors.
CONCLUSIONS: Lipiodol-DEB TACE was a safe option and associated with improved tumor response and survival outcome compared to DEB-TACE alone for selected patients with HCC.
摘要：
目的：本研究旨在提出一种新的碘油联合药物洗脱珠经动脉化疗栓塞术（Lipiodol-DEBTACE）的方法，并比较单独使用DEB-TACE治疗不可切除的肝细胞癌（HCC）患者的安全性和有效性。
方法：来自四个中心的数据库，对接受DEB-TACE或Lipiodol-DEBTACE作为初始治疗的HCC患者的记录进行回顾性评估.基于改良的实体瘤反应评估标准测量肿瘤反应。总生存期（OS），比较两组患者的无进展生存期(PFS)和不良事件(AE).
结果：共包括244例患者，其中160例患者接受DEB-TACE，84例患者接受Lipiodol-DEBTACE。Lipiodol-DEBTACE组客观缓解率较高（86.9%vs.76.3%），更高的疾病控制率（97.6%vs.88.8%），较长的中位数OS（42.6vs.25.8个月）和更长的中位PFS（34.0vs.17.0个月)优于DEB-TACE组(P<0.05)。两组之间的AE发生率没有显着差异。Cox分析确定总胆红素水平，肿瘤最大直径,TACE方法和门静脉侵犯为独立预后因素。
结论：对于选定的HCC患者，与单独的DEB-TACE相比，Lipiodol-DEBTACE是一种安全的选择，并且与改善的肿瘤反应和生存结局相关。
方法：来自四个中心的数据库，对接受DEB-TACE或Lipiodol-DEBTACE作为初始治疗的HCC患者的记录进行回顾性评估.基于改良的实体瘤反应评估标准测量肿瘤反应。总生存期（OS），比较两组患者的无进展生存期(PFS)和不良事件(AE).
结果：共包括244例患者，其中160例患者接受DEB-TACE，84例患者接受Lipiodol-DEBTACE。Lipiodol-DEBTACE组客观缓解率较高（86.9%vs.76.3%），更高的疾病控制率（97.6%vs.88.8%），较长的中位数OS（42.6vs.25.8个月）和更长的中位PFS（34.0vs.17.0个月)优于DEB-TACE组(P<0.05)。两组之间的AE发生率没有显着差异。Cox分析确定总胆红素水平，肿瘤最大直径,TACE方法和门静脉侵犯为独立预后因素。
结论：对于选定的HCC患者，与单独的DEB-TACE相比，Lipiodol-DEBTACE是一种安全的选择，并且与改善的肿瘤反应和生存结局相关。
